RTB brought up some good points about the new vide
Post# of 148162
(Total Views: 613)
Posted On: 05/31/2021 3:27:55 PM
RTB brought up some good points about the new video. At 31:10 Dr. Yang said "I've treated about 40 patients with open label compassionate use Leronlimab."
The excerpt below is Dr. Yang's answer in response to a question about immunorestoration vs. immunosuppressive that starts at 1:03:30. Nice to hear that their transplant surgeons are comfortable with Leronlimab.
https://www.youtube.com/watch?v=wDxOkdaQuec
I would call it immunomodulatory. I think calling it an immunosuppressive is wrong because it does not actually affect the function of the cells. It affects their trafficking so it affects the movement of the cells but it does not affect their ability to respond to pathogens. And so I would point out that, at least at our Center that has become a niche for Leronlimab because we are a very large transplant center, one of the biggest in the country, and the transplant surgeons are tremendously protective of their patients for good reason in terms of experimental treatments. But with Leronlimab they're fully comfortable, I must admit, because they have seen that it has had no issues with enhancing their immunosuppression and causing infection.
So I think it would be wrong to call it immunosuppressive. It's immunomodulatory, and when when the immune system is being thrown off balance by Covid-19, in that case then, it will help prevent cells from going where they shouldn't so restoring the balance that you expect. But I think when someone starts off with an immune system that's already fairly normal, like someone with treated HIV, it's going to have minimal effects because the cells are not trafficking abnormally there. So I think it's much more complex than just trying to classify it as immunosuppressive or even immunorestorative; it's immunomodulatory.
The excerpt below is Dr. Yang's answer in response to a question about immunorestoration vs. immunosuppressive that starts at 1:03:30. Nice to hear that their transplant surgeons are comfortable with Leronlimab.
https://www.youtube.com/watch?v=wDxOkdaQuec
I would call it immunomodulatory. I think calling it an immunosuppressive is wrong because it does not actually affect the function of the cells. It affects their trafficking so it affects the movement of the cells but it does not affect their ability to respond to pathogens. And so I would point out that, at least at our Center that has become a niche for Leronlimab because we are a very large transplant center, one of the biggest in the country, and the transplant surgeons are tremendously protective of their patients for good reason in terms of experimental treatments. But with Leronlimab they're fully comfortable, I must admit, because they have seen that it has had no issues with enhancing their immunosuppression and causing infection.
So I think it would be wrong to call it immunosuppressive. It's immunomodulatory, and when when the immune system is being thrown off balance by Covid-19, in that case then, it will help prevent cells from going where they shouldn't so restoring the balance that you expect. But I think when someone starts off with an immune system that's already fairly normal, like someone with treated HIV, it's going to have minimal effects because the cells are not trafficking abnormally there. So I think it's much more complex than just trying to classify it as immunosuppressive or even immunorestorative; it's immunomodulatory.
(11)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼